Less-invasive BPH (benign prostatic hyperplasia) treatment cleared for US sale:
This article was originally published in Clinica
The US FDA has cleared for sale Gyrus' Endourology system, which uses PlasmaKinetic radiofrequency technology to remove part of the prostate in patients with benign prostatic hyperplasia. The system is the third using PlasmaKinetic technology to be cleared by the FDA - the VAPR arthroscopy device and the VersaPoint hysteroscopic system are already sold in that market. The Cardiff, UK-based company now plans to begin discussions with potential US distributors for the Endourology system.
You may also be interested in...
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.